Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Resmed Inc
(NY:
RMD
)
225.86
-0.78 (-0.34%)
Official Closing Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Resmed Inc
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Analyst Ratings for ResMed
June 06, 2022
Analysts have provided the following ratings for ResMed (NYSE:RMD) within the last quarter:
Via
Benzinga
10 Biggest Price Target Changes For Monday
June 06, 2022
Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday.
Via
Benzinga
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
June 06, 2022
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Nasdaq tumbled over 300 points in the previous session despite better-than-expected jobs report for May.
Via
Benzinga
If You Invested $100 In Resmed 5 Years Ago, Here's How Much You Would Have Today
June 02, 2022
ResMed (NYSE:RMD) has outperformed the market over the past 5 years by 12.16% on an annualized basis producing an average annual return of 23.39%. Currently, ResMed has a market capitalization of...
Via
Benzinga
ResMed Earnings Perspective: Return On Invested Capital
May 03, 2022
Pulled from Benzinga Pro data, ResMed (NYSE:RMD) posted Q3 earnings of $179.01 million, an increase from Q2 of 11.27%. Sales dropped to $864.50 million, a 3.39% decrease between quarters.
Via
Benzinga
ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract
April 29, 2022
Via
Benzinga
What 5 Analyst Ratings Have To Say About ResMed
April 06, 2022
ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Expert Ratings For ResMed
January 31, 2022
ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:
Via
Benzinga
What 3 Analyst Ratings Have To Say About ResMed
April 29, 2022
Over the past 3 months, 3 analysts have published their opinion on ResMed (NYSE:RMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's...
Via
Benzinga
Earnings Outlook For ResMed
April 27, 2022
ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that ResMed will report an...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
April 06, 2022
Upgrades
Via
Benzinga
Recap: ResMed Q2 Earnings
January 27, 2022
ResMed (NYSE:RMD) reported its Q2 earnings results on Thursday, January 27, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings ResMed missed...
Via
Benzinga
Earnings Scheduled For January 27, 2022
January 27, 2022
Companies Reporting Before The Bell • SAP (NYSE:SAP) is estimated to report quarterly earnings at $1.87 per share on revenue of $9.10 billion. •...
Via
Benzinga
Ten Healthcare Companies With High Payout Ratio
March 25, 2022
The healthcare industry is among the biggest U.S. market segments in terms of market capitalization, but when it comes to dividend payouts, they rank very low.
Via
Talk Markets
3 Top S&P 500 Stock Market Gainers Today: Energy Dominates As Adobe Dives
March 23, 2022
Energy and commodity plays were top performers Wednesday.
Via
Investor's Business Daily
Markets Fall Amid Rising Oil Prices
March 23, 2022
U.S. indices finished lower Wednesday as investors continue to weigh the Federal Reserve tapering outlook, inflation concerns and the Russia-Ukraine war. Oil prices have also...
Via
Benzinga
3 Beaten-Down Growth Stocks With More Than 50% Upside Potential
February 25, 2022
The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions.
Via
InvestorPlace
Ominous Death Cross Forms On ResMed's Chart
February 02, 2022
If history is any guide, there may be trouble ahead for shares of ResMed (NYSE:RMD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
Sleep Apnea Device Maker Resmed Sees Improved Relative Strength
January 14, 2022
Resmed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
ResMed's Return on Invested Capital Overview
January 28, 2022
According to Benzinga Pro, during Q2, ResMed (NYSE:RMD) earned $201.75 million, a 0.91% increase from the preceding quarter. ResMed's sales decreased to $894.87 million, a 1.01%...
Via
Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
January 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
ResMed Q2 Earnings Highlights: Supply Chain Constraints, Unlimited Demand Due To Competitor Recall
January 28, 2022
ResMed Inc (NYSE: RMD) revealed a 13% Y/Y jump in Q2 FY22 revenue to $894.9 million, missing the consensus of $935.25 million. The growth was below analyst expectations...
Via
Benzinga
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
January 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Preview: ResMed
January 26, 2022
ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-01-27. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
January 23, 2022
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...
Via
Benzinga
This Company Just Made a Possibly Lucrative Acquisition — What's Next?
January 14, 2022
Photo by Ccfb on Pixabay This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The global...
Via
Benzinga
What 4 Analyst Ratings Have To Say About ResMed
January 13, 2022
Within the last quarter, ResMed (NYSE:RMD) has observed the following analyst ...
Via
Benzinga
Take Action To Unlock Supply Chain Disruption Issues
January 07, 2022
Businesses are grappling with supply chain disruption. And beating this challenge requires leaders to take decisive action right now.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 13, 2022
January 13, 2022
Upgrades According to Morgan Stanley, the prior rating for SunPower Corp (NASDAQ:
Via
Benzinga
4 Low-Beta Stocks To Buy For A Volatile Market
December 08, 2021
Global economic uncertainty, inflationary pressure, a disappointing jobs report, and concerns around the COVID-19 Omicron variant are fostering market volatility. So, against this backdrop, we think it...
Via
Talk Markets
Exposures
COVID-19
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.